Quote | Super Quote
22504 CIHRPHA@EC2610A (CALL)
RT Nominal down0.188 -0.008 (-4.082%)

25/09/2025 14:47

{I-bank focus}Nomura keeps Hengrui Pharma at HKD94.54

[ET Net News Agency, 25 September 2025] Nomura kept the target price for Hengrui Pharma
(01276) at HKD94.54 and maintained the "buy" rating.
Hengrui announced its fifth out-licensing deal of this year, whereby it has agreed to
grant licence for trastuzumab rezetecan (SHR-A1811, a HER2 ADC) to Glenmark Specialty, a
wholly-owned subsidiary of Glenmark Pharmaceuticals. The research house said the milestone
size in this deal is quite good for Hengrui. Partnering with Glenmark in these markets can
also help Hengrui unlock the commercial potential. (rc)

Back to Related News

Remark: Real time quote last updated: 02/12/2025 17:59
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2025 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.